Breaking News

PPD Names Health Outcomes VP

By Kristin Brooks | March 20, 2014

Pollock to direct health outcomes and evidence-based medicine

Michael Pollock has been appointed vice president of real world outcomes at Pharmaceutical Product Development, LLC (PPD). Mr. Pollock is responsible for directing and enhancing the company’s capabilities in health outcomes and evidence-based medicine to help biopharmaceutical clients optimize market and patient access to novel therapies.
Most recently, Mr. Pollock was president of Reynolds Pollock & Associates, a health outcomes research and market access strategy consulting company. He also held roles as vice president of global health economics at Biogen Idec, vice president of sales and marketing at Elan Pharmaceuticals, vice president of sales and marketing and information services at Oncology Therapeutics Network, a division of Bristol-Myers Squibb, and director and head of worldwide health economics at Glaxo Wellcome.

“PPD is continually strengthening its offerings across the real world outcomes spectrum, and Michael brings a unique background to this role, having held senior positions both in sales and marketing, and in health economics for both large pharmaceutical and biotechnology companies,” said Rob Dow, M.D., PPD’s senior vice president of medical affairs. “He has the knowledge, experience and leadership skills to help grow PPD’s real world outcomes solutions, as we drive value and fuel success for clients.”
PPD tailors real world outcomes studies for clients aimed at providing flexible designs that meet specific objectives, marketplace needs and regulatory requirements in the post-approval environment.
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.